RECENT NEWS

For Media Inquiries

Melissa Andrews, Director of Marketing
970-926-1277 / mandrews@cando-ms.org

Media Kit

First
1
2
3
4
5
6
Last

What’s Top of Mind for People with Multiple Sclerosis?

September 15th, 2019

New Research from Can Do MS and EMD Serono Identifies Financial Planning and Staying in the Workplace as Critical Concerns in Managing Unpredictable Disease

Support Can Do MS by buying Super Rad Raygun this month

September 6th, 2019

Independent game developers Chris Bryant and Chris Hernandez are raising money for families living with MS. All revenue for Super Rad Raygun on itch.io during the month of September will be donated to Can Do MS!

This September, show the world how you #KickMS to inspire others and spread awareness of multiple sclerosis

September 3rd, 2019

Can Do Multiple Sclerosis launched their annual, online campaign that encourages people living with MS, as well as their friends and supporters, to share how they thrive with MS during September’s Can Do Month celebration.

Pro Cyclist Tyler Hamilton’s Annual MS Global Bike Tour Comes to Nova Scotia to Raise Funds for Multiple Sclerosis

August 16th, 2019

MS Global 2019, a seven-day annual charitable bicycle tour founded by former professional cyclist Tyler Hamilton to raise funds for families with multiple sclerosis (MS), will be held in Cape Breton Island, Nova Scotia from Sept. 14 to Sept. 22.

FDA approves new oral drug to treat multiple sclerosis

April 2nd, 2019

The U.S. Food and Drug Administration approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis

April 2nd, 2019

EMD Serono announced that the U.S. Food and Drug Administration has approved MAVENCLAD® (cladribine) tablets for the treatment of adults with relapsing-remitting disease and active secondary progressive disease.

Lokai Launches Multiple Sclerosis Teal Bracelet

March 4th, 2019

Lokai, the socially responsible brand representing the importance of finding balance along life’s journey, announced a new teal bracelet in partnership with Can Do Multiple Sclerosis (Can Do MS).

FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis

December 17th, 2018

BrainStorm Cell Therapeutics Inc. announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of NurOwn® for the treatment of progressive multiple sclerosis.

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

December 17th, 2018

Diroximel fumarate was designed to provide patients with relapsing forms of multiple sclerosis a novel oral fumarate with a differentiated profile. The data encompassed in the regulatory package underscore diroximel fumarate’s potential to be a meaningful, new treatment option for the MS community.

Can Do MS Retains Highest Recognition from Charity Navigator

December 14th, 2018

This is the 10^th time that Can Do MS has earned a 4-star rating from Charity Navigator, showing the organization uses donor dollars in a fiscally responsible way to further its mission of delivering health and wellness education programs that help families with MS thrive.

First
1
2
3
4
5
6
Last